ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Services

ReproCELL Inc.

Business Summary

ReproCELL Inc. engages in stem cell research. It operates through the following segments: Research Support and Medical. The Research Support segment includes reagents and drug discovery support in the Induced Pluripotent Stem (iPS) cell business. The Medical segment deals with regenerative medicine in the iPS cell business and clinical testing services. The company was founded by Norio Nakatsuji and Hiromitsu Nakauchi on February 26, 2003 and is headquartered in Yokohama, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue1,286.28M12.12M
Gross Profit456.09M4.30M
Operating income-1,048.04M-9.88M
Income before tax-811.93M-7.65M
Net income-812.57M-7.66M
EBITDA-962.62M-9.07M
Diluted EPS-11.37-0.10
Dividends Per Share00
Total Assets6,047.48M54.72M
Total liabilities656.43M5.94M
Total equity5,384.41M48.72M
Operating cash flow-648.88M-6.11M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 1,257.81M 926.25M 1,088.52M 1,199.90M 1,286.28M
Gross Profit 342.51M 146.68M 461.86M 433.27M 456.09M
Operating income -944.30M -1,025.78M -781.11M -908.93M -1,048.04M
Income before tax -937.07M -2,281.55M -627.09M -1,015.18M -811.93M
Net income -911.66M -2,172.04M -601.42M -1,016.52M -812.57M
EBITDA -689.15M -772.29M -704.77M -818.73M -962.62M
Diluted EPS -15.68 -34.28 -8.79 -14.26 -11.37
Dividends Per Share 0 0 0 0 0
Total Assets 7,854.11M 6,597.79M 7,489.99M 6,553.04M 6,047.48M
Total liabilities 485.59M 349.37M 418.84M 494.89M 656.43M
Total equity 7,368.52M 6,248.41M 7,069.96M 6,050.57M 5,384.41M
Operating cash flow -775.02M -636.72M -554.83M -689.80M -648.88M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 11.61M 8.35M 9.81M 11.03M 12.12M
Gross Profit 3.16M 1.32M 4.16M 3.98M 4.30M
Operating income -8.72M -9.25M -7.04M -8.35M -9.88M
Income before tax -8.65M -20.58M -5.65M -9.33M -7.65M
Net income -8.41M -19.59M -5.42M -9.34M -7.66M
EBITDA -6.36M -6.96M -6.35M -7.53M -9.07M
Diluted EPS -0.14 -0.30 -0.07 -0.13 -0.10
Dividends Per Share 0 0 0 0 0
Total Assets 70.48M 62.03M 67.66M 60.70M 54.72M
Total liabilities 4.35M 3.28M 3.78M 4.58M 5.94M
Total equity 66.12M 58.75M 63.87M 56.04M 48.72M
Operating cash flow -7.15M -5.74M -5.00M -6.34M -6.11M

Valuation Measures

Mar 2021
PER--
ROA-12.89%
ROE-14.21%
Operating margin-81.47%
Profit margin-63.17%

Key executives

  • President & Representative Director: Chikafumi Yokoyama
  • Chief Operating Officer & Director: Daisuke Usui
  • CFO & Senior Manager-Business Administration: Shigetomo Akano

Shareholders

  • YOKOYAMA CHIKAFUMI (1.3%)
  • ISOHATA TERUO (1.1%)
  • NAKATSUJI NORIO (0.6%)
  • Reprocell Restricted Stock Compensation Plan (0.6%)
  • SSgA Funds Management, Inc. (0.4%)
  • KATAYAMA HIROMI (0.3%)
  • OHTA SHOICHI (0.3%)
  • SHIMOMURA MINORU (0.3%)
  • Nissan Chemical Corp. (0.1%)
  • Cosmo Bio Co., Ltd. (0.1%)

Contact Details

  • Website:http://www.reprocell.co.jp
  • Address: Metlife Shin-Yokohama Building, 9/F, 3-8-11 Shin-Yokohama, Yokohama, 222-0033, Japan
  • Phone: +81.45.475.3887

Related Companies

  • MAGiQ Therapeutics KK
  • Reprocell Restricted Stock Compensation Plan
  • ReproCELL Europe Ltd.
  • Stemgent, Inc. /New/
  • RC Partners, Inc.
  • ReproCELL USA Inc.
  • Reinnervate Ltd.
  • Bioserve Biotechnologies (India) Pvt Ltd.
  • Biopta Ltd.
  • BioServe Biotechnologies Ltd.

Competitors

    Last Updated on 15 Oct, 2021

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Try 1 month for $0.99

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world
    .

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends October 31st

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to Nikkei Asia has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media

    Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

    Celebrate our next chapter
    Free access for everyone - Sep. 30

    Find out more